Serum biomarkers for glioblastoma multiforme

Ayesha Quddusi, Muhammad Shahzad Shamim

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


A number of different serum biomarkers are currently being evaluated for their potential use as diagnostic and prognostic biomarkers in Glioblastoma Multiforme. Amongst these, a vast number of different microRNAs have been studied, that are up-regulated or downregulated in relation to Glioblastoma Multiforme. Different studies have found numerous associations of these different microRNAs with recurrence, Karnofsky Performance Score, Progression Free Survival and Overall Survival. Other than microRNAs, serum Glial Fibrillary Acid Protein, cytokines and YLK-40, as well as a number of other candidate serum biomarkers are being studied.More studies, with larger sample sizes are required before these serum biomarkers can be routinely, and reliably used in clinical practice. Use of serum biomarkers can provide a non-invasive means for diagnosing and monitoring disease.

Original languageEnglish
Pages (from-to)913-914
Number of pages2
JournalJPMA. The Journal of the Pakistan Medical Association
Issue number6
Publication statusPublished - 1 Jun 2019


  • Glioblastoma multiforme, Serum biomarkers, microrna, GFAP, YLK-40.


Dive into the research topics of 'Serum biomarkers for glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this